CytoMed Therapeutics Limited Ordinary Shares (GDTC)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$0.88

+0.02 (+2.57%)

Market Cap: $10.26M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

60%(6/10)

Avg Surprise

-63.33%

Streak

1 Q

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Mar 31, 2026Mar 26 Reported Apr 27, 2026Reported Apr 27	$0.00	N/A	-	+100.00%	Beat	-	-	-
Sep 30, 2025Sep 25 Reported Oct 2, 2025Reported Oct 2	$-0.19	$-0.04	-	-375.00%	Miss	-	-	-375.0%
Jun 30, 2025Jun 25 Reported Sep 30, 2025Reported Sep 30	$N/A	$0.00	$0.00 - $0.00	N/A	Beat	0	1 0 30d	-
Mar 31, 2025Mar 25 Reported Apr 28, 2025Reported Apr 28	$-0.12	$-0.04	$-0.04 - $-0.04	-200.00%	Miss	1	1 0 30d	-200.0%
Dec 31, 2024Dec 24 Reported Mar 31, 2025Reported Mar 31	$N/A	$-0.04	-	N/A	Beat	1	1 0 30d	-
Sep 30, 2024Sep 24 Reported Nov 27, 2024Reported Nov 27	$-0.04	$-0.04	-	+0.00%	Beat	-	-	+50.0%
Jun 30, 2024Jun 24 Reported Sep 30, 2024Reported Sep 30	$-0.09	$-0.04	$-0.04 - $-0.04	-125.00%	Miss	1	1 0 30d	-50.0%
Mar 31, 2024Mar 24 Reported May 6, 2024Reported May 6	$-0.04	$-0.04	$-0.04 - $-0.04	+0.00%	Beat	1	1 0 30d	+33.3%
Dec 31, 2023Dec 23 Reported Feb 28, 2024Reported Feb 28	$-0.05	$-0.05	-	+0.00%	Beat	0	No revisions (30d)	-
Sep 30, 2023Sep 23 Reported Nov 17, 2023Reported Nov 17	$-0.08	$-0.06	-	-33.33%	Miss	-	-	-
Jun 30, 2023Jun 23 Reported Aug 30, 2023Reported Aug 30	$-0.06	$-0.06	$-0.06 - $-0.06	+0.00%	Beat	0	No revisions (30d)	-
Mar 31, 2023Mar 23 Reported May 1, 2023Reported May 1	$-0.06	$-0.06	$-0.06 - $-0.06	+0.00%	Beat	0	No revisions (30d)	-

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	-1.66x	FCF Yield	-60.14%
Profitability
Profit Margin	0.00%	Operating Margin	-476.10%
ROE	-56.20%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	-183.93x
Current Ratio	2.64x	Quick Ratio	2.64x
Trading Statistics
Beta	0.07	Avg Volume	20.76K
52-Week High	$3.68	52-Week Low	$0.68

Technical Indicators Dashboard

Moving Averages

SMA 10$0.91

SMA 20$0.91

SMA 50$0.90

SMA 200$1.00

EMA 10$0.89

EMA 20$0.90

EMA 50$0.91

EMA 200$1.11

MACD

Line: -0.01Signal: 0.00Hist: -0.01

ADX

ADX: 17.0+DI: 12.2-DI: 24.9

Aroon & PSAR

Aroon Up68.0

Aroon Down88.0

PSAR$1.04

Bollinger Bands

Upper Band$1.01

Lower Band$0.81

%B Position2176%(Upper)

Band Width0.34

RSI (14-Day)

Neutral

48.4

Momentum Oscillators

Stoch %K45.4

Stoch %D40.8

Williams %R-51.3

ROC (10d)-2.0%

Momentum-0.02

CCI (20d)-122.3

MFI (14d)44.2

Volatility Measures

ATR (14d)$0.12(13.1%)

StdDev (20d)0.05

Hist Vol92.9%(High)

Volume Flow

VWAP$0.83

OBV15.3M

AD Line9.1M

CMF (20d)0.616

Volume Metrics

Avg Vol (20d)22.3K

Vol Ratio0.4x(Low)

VWMA (20d)$0.92

Pivot Points

R3$0.94

R2$0.90

R1$0.88

Pivot Point$0.85

S1$0.82

S2$0.79

S3$0.77

Advanced Oscillators

TSI-2.04

Ultimate Osc69.9

KST20.22

Financial Data

Quarter	Jun 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Total Revenue	$157,673	$167,945	$205,081	$134,896	$134,721	$141,701	$112,038	$112,385	N/A	$111,956	$142,249	$141,851
Cost of Revenue	$534,282	$723,598	$31,988	$9,349	N/A	$14,637	$1,103	$1,106	$38,231	$1,187	$205,722	$3,043
Gross Profit	$-376,609	$-555,651	$173,092	$125,547	$125,385	$127,065	$110,935	$111,278	$-38,231	$110,769	$-63,472	$138,806

Operating Expenses	$1.63M	$1.80M	$834,204	$777,092	$776,087	$646,066	$641,162	$643,153	$1.48M	$548,379	$492,507	$491,128
R&D	$1.10M	$1.05M	$527,514	$583,345	$582,591	$474,620	$858,882	$488,482	$576,611	$389,888	$406,053	$404,916
SG&A	$0	$0	$285,314	$0	$161,290	$163,762	$149,876	$150,341	$0	$154,013	$684,760	$74,050
Operating Income	$-2,007,065	$-2,356,388	$-661,112	$-651,544	$-650,703	$-519,000	$-530,227	$-531,872	$-1,516,560	$-437,608	$-1,575,424	$-1,012,924

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$10,163	$10,560	$5,092	$9,938	$5,165	$208,481	$9,863	$10,316	$0	$551,308	$41,285	$61,000
Income Before Tax	$-1,798,534	$-1,744,762	$-875,254	$-1,126,993	$-1,125,537	$-727,481	$-544,014	$-545,704	$-1,454,043	$-988,916	$-2,186,247	$-1,077,147
Income Tax Expense	$0	$0	$0	$0	$0	$0	$569,042	$0	$0	$0	$14,676	$0

Net Income	$-1,774,782	$-1,730,996	$-868,349	$-1,125,955	$-1,124,500	$-724,934	$-1,095,028	$-545,630	$-1,462,903	$-989,175	$-1,080,104	$-1,077,077

EBITDA	$-1,864,825	$-2,224,675	$-986,634	N/A	$-1,025,118	$-668,826	N/A	$-743,482	$-1,478,330	$-820,181	N/A	$-911,565
EBIT	$-2,007,064	$-2,356,388	$-1,097,696	N/A	$-1,115,057	$-751,476	N/A	$-827,136	$-1,516,561	$-908,275	N/A	$-1,012,923

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about GDTC

News

Form 13D/A CytoMed Therapeutics Ltd For: 16 October By Investing.com

This article announces the filing of Form 13D/A for CytoMed Therapeutics Ltd on October 16. It is a brief, news-style piece published by Investing.com...

Investing.com UK•Oct 16, 2026 7:12 AM ET10/16/26•Neutral

The chairman bought 29,250 shares in CytoMed Therapeutics (NASDAQ: GDTC) and reported his stake.

CytoMed Therapeutics' Chairman and Director, Choo Chee Kong, purchased 29,250 ordinary shares on the Nasdaq Capital Market between October 12-15, 2026...

Stock Titan•Oct 16, 2026 6:12 AM ET10/16/26•Neutral

CytoMed Therapeutics (NASDAQ: GDTC) chairman buys shares, reports a 24.92% stake.

CytoMed Therapeutics' Chairman and Director, Choo Chee Kong, acquired 62,000 ordinary shares through open-market purchases between October 5 and October 8, 2026...

Stock Titan•Oct 13, 2026 6:41 AM ET10/13/26•Bullish

30 days below $1 triggers a Nasdaq notice for CytoMed (Nasdaq: GDTC). Trading is unaffected for now.

CytoMed Therapeutics Limited (Nasdaq: GDTC) received a Nasdaq notice on October 6, 2026, because its share price stayed below $1.00 for 30 consecutive business days. The company has until April 5, 2027...

Stock Titan•Oct 10, 2026 11:41 AM ET10/10/26•Bearish

CytoMed receives Nasdaq minimum bid price deficiency notice By Investing.com

CytoMed Therapeutics Limited received a notice from Nasdaq indicating its ordinary shares fell below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 calendar days, until April 5, 2027...

Investing.com Nigeria•Oct 10, 2026 4:44 AM ET10/10/26•Bearish

GDTC Valuation and Fair Value

P/FCF: -1.7x
P/B: 2.1x

See GNG's fair value

GDTC Profitability: Margins, ROIC and FCF

Gross margin: -95.2%
Operating margin: -476.1%
Net margin: 0.0%
ROE: -56.2%
FCF margin: -946.8%
FCF yield: -60.1%

GDTC Competitors

Company	Ticker
NLS Pharmaceutics AG	NLSP
Biovie Inc	BIVI
Cytosorbents Crp	CTSO
Lantern Pharma Inc	LTRN
Phio Pharmaceuticals Corp	PHIO
Bullfrog AI Holdings, Inc. Common Stock	BFRG
Ensysce Biosciences Inc	ENSC
Karyopharm Therapeutics Inc	KPTI

Sector: Healthcare

GDTC Bull Case vs Bear Case

Bear case

GDTC beat EPS estimates in 12.5% of its last 8 reported quarters.
GDTC's quarterly revenue changed -15.9% year over year.

GDTC Earnings: Beat Rate and Next Report

Beat rate: 1 of 8 quarters (12.5%)
Average surprise: -79.2%

Frequently Asked Questions About GDTC

Does GDTC pay dividends?

CytoMed Therapeutics Limited Ordinary Shares (GDTC) does not currently pay a regular dividend.

What is GDTC's market cap?

CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a market capitalization of $10.26M with a current stock price of $0.88.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In